On November 13, 2014, Chief ALJ Charles E. Bullock issued Order No. 62 in Certain Antivenom Compositions and Products Containing the Same (Inv. No. 337-TA-903).
By way of background, the investigation is based on an October 20, 2013 complaint filed by BTG International Inc. ("BTG") alleging violations of Section 337 in the importation into the U.S. and sale of certain antivenom compositions and products containing the same that infringe one or more claims of the '414 patent. See our November 1, 2013 and December 2, 2013 posts for more details on the complaint and the Notice of Investigation, respectively. The remaining Respondents are Laboratorios Silanes S.A. de C.V., Instituto Bioclon S.A. de C.V., and Rare Disease Therapeutics, Inc. (collectively, "Respondents").
In the Order, ALJ Bullock granted a joint motion filed by BTG and Respondents to terminate the investigation in its entirety based on a settlement agreement between the parties.